⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Censoring rules 3 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

David S. Hong Michael A. Postow Bartosz Chmielowski Ryan J. Sullivan Amita Patnaik Ezra E.W. Cohen Geoffrey I. Shapiro Conor Steuer Martin Gutierrez Heather Yeckes-Rodin Robert Ilaria Brenda O’Connell Joanna Peng Guangbin Peng Nora Zizlsperger Anthony W. Tolcher Jedd D. Wolchok

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Study IPI-549-01 progression-free survival censoring rules for efficacy analyses

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hong et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587523029 https://doi.org/10.1158/1078-0432.27030673

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Inclusion and Exclusion Criteria 1 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
2Table S4 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
3Table S4 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
4Table S3 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
5Table S3 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024

More related papers

Table S2 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
Table S2 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
Table S1 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024